DALLAS, Aug. 24, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring AVI BioPharma Inc. (Nasdaq:AVII). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/AVII
AVI BioPharma Inc. (AVII) is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid (RNA)-based drugs targeting a range of diseases. The Company has developed and optimized derivatives of its antisense chemistry (phosphorodiamidate morpholino oligomers (PMOs)) that can be designed to target disease mechanisms through mechanisms of action. The applications of AVII's RNA technology platform include genetic diseases (Duchenne muscular dystrophy (DMD)), infectious diseases (Ebola and Marburg viruses), cardiovascular disease (restenosis) and other early discovery targets. Several of its antiviral programs, including Ebola, Marburg, Junin and Dengue, have been or are funded by the United States government, and other governmental and non-governmental funding. On March 20, 2008, the Company acquired Ercole Biotechnology Inc.
Message Board Search for AVII: http://www.boardcentral.com/boards/AVII
In the report, the analyst notes:
"For the second quarter of 2010 AVII reported an operating loss of $7.7 million compared with an operating loss of $5.1 million in the second quarter of 2009. The increase in the operating loss is the result of a $2.6 million one-time charge for severance and stock compensation costs related to the April 2010 departure of AVII's former chief executive off.
"AVII recently announced the publication online in Nature Medicine of new preclinical data demonstrating that AVI-6002 and AVI-6003, the respective lead therapeutic candidates against Ebola and Marburg viruses, both employing AVII's advanced PMOplus(TM) chemistry, provide post exposure efficacy in non-human primates."
To read the entire report visit: www.microstockprofit.com/lp/AVII
See what investors are saying about AVII at http://www.stockhideout.com
Get breaking news on AVII at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.